• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bacillus Anthracis Infections - Pipeline Review, H2 2012 Product Image

Bacillus Anthracis Infections - Pipeline Review, H2 2012

  • Published: October 2012
  • 112 pages
  • Global Markets Direct

Bacillus Anthracis Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bacillus Anthracis Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacillus Anthracis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacillus Anthracis Infections. Bacillus Anthracis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacillus Anthracis Infections.
- A review of the Bacillus Anthracis READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Bacillus Anthracis Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Bacillus Anthracis Infections 11
Bacillus Anthracis Infections Therapeutics under Development by Companies 13
Bacillus Anthracis Infections Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Bacillus Anthracis Infections Therapeutics – Products under Development by Companies 21
Bacillus Anthracis Infections Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Bacillus Anthracis Infections Therapeutics Development 23
Aradigm Corporation 23
AlphaRx, Inc. 24
Bavarian Nordic A/S 25
Emergent BioSolutions Inc. 26
Human Genome Sciences, Inc. 27
Oragenics, Inc. 28
PharmAthene, Inc. 29
Soligenix, Inc. 30
Elusys Therapeutics, Inc. 31
Green Cross Corporation 32
Panacea Biotec Limited 33
PolyMedix, Inc. 34
Evolva SA 35
Vaxin, Inc. 36
Phage Biotechnology Corporation 37
Exponential Biotherapies, Inc. 38
NanoBio Corporation 39
ImmunoVaccine Technologies Inc. 40
iBio, Inc. 41
Tetraphase Pharmaceuticals Inc. 42
NasVax Ltd. 43
Pfenex Inc. 44
VectorLogics, Inc. 45
Bacillus Anthracis Infections – Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
raxibacumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Valortim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ciprofloxacin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ciprofloxacin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MVA-BN Anthrax - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Anthrivig - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Thravixa - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MU-1140 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
EV-021 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drug For Anthrax - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
oritavancin disphosphate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CST-102 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ETI-204 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
EV-009 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PMX-30016 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Alpha-1 Antitrypsin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Anthrax Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AV-7909 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AdVAV Anthrax Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Epicutaneous Anthrax Vaccines - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
VeloThrax - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GC-1109 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SMT-15000 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Anthrax Vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Anthrax Monoclonal Antibody - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Anthrax Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PreviThrax - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Anthrax Vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TP-271 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
VLI-04A - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
EV-035 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
doxycycline - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Anthrax Capsule Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Snare Antibacterial For Anthrax - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Vaccine Adjuvant - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Anthrax Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Bacillus Anthracis Infections Therapeutics – Drug Profile Updates 93
Bacillus Anthracis Infections Therapeutics – Discontinued Products 102
Bacillus Anthracis Infections Therapeutics - Dormant Products 103
Bacillus Anthracis Infections – Product Development Milestones 104
Featured News & Press Releases 104
Sep 13, 2012: Elusys Therapeutics Receives $14.5m Additional Fund From US Government To Develop Anthim 104
Aug 02, 2012: Elusys Receives Additional $50.2m From US Government Contract To Support Development Of ETI-204 For Treatment Of Inhalational Anthrax 105
Jul 10, 2012: Human Genome Sciences Announces Resubmission Of Raxibacumab BLA To FDA 105
Jun 04, 2012: Emergent Secures Additional Funding From BARDA To Pursue Post-Exposure Prophylaxis Indication For BioThrax 106
May 17, 2012: Emergent Receives FDA Approval For BioThrax Administered Intramuscularly In Three-Dose Primary Series Followed By Booster Doses 107
May 01, 2012: BARDA Exercises Option With Pfenex To Extend Contract To Develop Anthrax Vaccine 107
Dec 06, 2011: Pharmathene Announces Publication Of Phase I Study Results For Anthrax Anti-toxin Valortim 108
Nov 17, 2011: Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating Three-Dose BioThrax Regimen For Post-Exposure Prophylaxis 109
Oct 24, 2011: Elusys Initiates Third Clinical Safety Study Of Anthim 109
Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 112
Disclaimer 112

List of Tables
Number of Products Under Development for Bacillus Anthracis Infections, H2 2012 11
Products under Development for Bacillus Anthracis Infections – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Aradigm Corporation, H2 2012 23
AlphaRx, Inc., H2 2012 24
Bavarian Nordic A/S, H2 2012 25
Emergent BioSolutions Inc., H2 2012 26
Human Genome Sciences, Inc., H2 2012 27
Oragenics, Inc., H2 2012 28
PharmAthene, Inc., H2 2012 29
Soligenix, Inc., H2 2012 30
Elusys Therapeutics, Inc., H2 2012 31
Green Cross Corporation, H2 2012 32
Panacea Biotec Limited, H2 2012 33
PolyMedix, Inc., H2 2012 34
Evolva SA, H2 2012 35
Vaxin, Inc., H2 2012 36
Phage Biotechnology Corporation, H2 2012 37
Exponential Biotherapies, Inc., H2 2012 38
NanoBio Corporation, H2 2012 39
ImmunoVaccine Technologies Inc., H2 2012 40
iBio, Inc., H2 2012 41
Tetraphase Pharmaceuticals Inc., H2 2012 42
NasVax Ltd., H2 2012 43
Pfenex Inc., H2 2012 44
VectorLogics, Inc., H2 2012 45
Assessment by Monotherapy Products, H2 2012 46
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Stage and Molecule Type, H2 2012 51
Bacillus Anthracis Infections Therapeutics – Drug Profile Updates 93
Bacillus Anthracis Infections Therapeutics – Discontinued Products 102
Bacillus Anthracis Infections Therapeutics – Dormant Products 103

List of Figures
Number of Products under Development for Bacillus Anthracis Infections, H2 2012 11
Products under Development for Bacillus Anthracis Infections – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 46
Assessment by Route of Administration, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Molecule Type, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 50

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos